CRISPR Therapeutics Q4 net loss $37.3M; cash at $1.9B; 50+ ATCs activated

CRISPR Therapeutics AG

2024-FY EPS reported -$4.34 revenue$37,314,000

Q4 2024 net loss of $37.3M vs net income of $89.3M in Q4 2023.
Cash, cash equivalents, and marketable securities of $1,903.8M, up from $1,695.7M a year earlier.
Over 50 authorized treatment centers activated globally for CASGEVY; >50 patients have had cells collected.
R&D expenses fell to $82.2M in Q4 2024 from $95.1M in Q4 2023.
Pipeline catalysts in 2025: CTX112 updates mid-2025; CTX310/320 updates H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.